Acorda Therapeutics develops and sells treatments for neurological disorders, such as Ampyra for MS patients and Inbrija for Parkinson's disease in Europe, among others. The New York-based biopharmaceutical company also develops potential treatments for acute migraines, heart failure patients, and MS patients through their agreement with Biogen Inc. Acorda Therapeutics’ mission is to help improve the quality of life for those impacted by neurological issues.